Evaluation of BBIBP-CorV Sinopharm COVID-19 vaccine effectiveness in Sri Lanka: a test-negative case control study
Authors:
- Shamila Thivanshi De SilvaSSShamila Thivanshi De Silva
- Dileepa Senajith EdiriweeraDEDileepa Senajith Ediriweera
- Wathsala WimalasenaWWWathsala Wimalasena
- Manjula KariyawasamMKManjula Kariyawasam
- Gihan KosinnaGKGihan Kosinna
- Gayan BogodaGBGayan Bogoda
- Sumudu SenaratneSSSumudu Senaratne
- Kanchana RathnayakeKRKanchana Rathnayake
- Inosha WeerarathnaIWInosha Weerarathna
- Ranjan PremaratnaRPRanjan Premaratna
- Prasanna GunasenaPGPrasanna Gunasena
Open Access
Abstract
Objectives There is limited research on real-world effectiveness of BBIBP-CorV Sinopharm COVID-19 vaccine. This study evaluated real-world effectiveness of Sinopharm vaccine in Sri Lanka by assessing absolute vaccine efficacy. Design and setting A retrospective test-negative case-control study was conducted at ten large government hospitals across the country. Participants Consecutive adults aged ≥18 years attending outpatient departments who tested reverse-transcription-PCR positive for SARS-CoV-2 during the study period were recruited. Main outcome measures An interviewer-administered questionnaire was administered, and outcome of COVID-19 infection was assessed in cases. Results Of 1829 recruited, 914 (49.9%) were male, and mean age was 45.2 (SD 15.3) years; 1634 (89.3%) were vaccinated with two doses of BBIBP-CorV Sinopharm vaccine, while 195 (10.1%) were vaccine-naïve. Compared with the vaccinated, unvaccinated persons were older but otherwise similar in their demographic and medical profiles. Unvaccinated were more likely to have fever, shortness of breath and vomiting as symptoms and were more likely to seek treatment. Significantly more vaccinated individuals received treatment at home. After admission, the unvaccinated were more likely to receive oxygen. Significantly more unvaccinated persons died of COVID-19 compared with the vaccinated. Sinopharm vaccine was 78.2% (94% CI 69.0% to 85.0%) effective at preventing COVID-19 infection, 88.7% (81.6%–93.2%) effective at preventing severe infection and 85.6% (69.6%–93.6%) effective at preventing death. Conclusions BBIBP-CorV Sinopharm vaccine is effective at mitigating severity of illness and reducing the likelihood of hospitalisation, severe illness and death, in those who received primary vaccination, compared with the unvaccinated.Keywords
Funding Information
- State Pharmaceutical Corporation of Sri Lanka
This publication has 17 references indexed in Scilit:
- Effectiveness of BNT162b2 and ChAdOx1 nCoV-19 COVID-19 vaccination at preventing hospitalisations in people aged at least 80 years: a test-negative, case-control studyThe Lancet Infectious Diseases, 2021
- Assessing COVID-19 Vaccine Uptake and Effectiveness Through the North West London Vaccination Program: Retrospective Cohort StudyJMIR Public Health and Surveillance, 2021
- FDA-authorized mRNA COVID-19 vaccines are effective per real-world evidence synthesized across a multi-state health systemMed, 2021
- Interim Estimates of Vaccine Effectiveness of Pfizer-BioNTech and Moderna COVID-19 Vaccines Among Health Care Personnel — 33 U.S. Sites, January–March 2021MMWR. Morbidity and Mortality Weekly Report, 2021
- Global burden of COVID-19: Situational analyis and reviewHuman Antibodies, 2021
- Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control studyBMJ, 2021
- Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Among Hospitalized Adults Aged ≥65 Years — United States, January–March 2021MMWR. Morbidity and Mortality Weekly Report, 2021
- COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort studyThe Lancet, 2021
- SARS-CoV-2 Vaccines and the Growing Threat of Viral VariantsJAMA, 2021
- The epidemiology and clinical information about COVID-19European Journal of Clinical Microbiology & Infectious Diseases, 2020